Novel Prognostic Markers in Triple-Negative Breast Cancer Discovered by MALDI-Mass Spectrometry Imaging

There are no widely-accepted prognostic markers currently available to predict outcomes in patients with triple-negative breast cancer (TNBC), and no targeted therapies with confirmed benefit. We have used MALDI mass spectrometry imaging (MSI) of tryptic peptides to compare regions of cancer and ben...

Descripción completa

Detalles Bibliográficos
Autores principales: Phillips, Leo, Gill, Anthony J., Baxter, Robert C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6527753/
https://www.ncbi.nlm.nih.gov/pubmed/31139569
http://dx.doi.org/10.3389/fonc.2019.00379

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6527753/
https://www.ncbi.nlm.nih.gov/pubmed/31139569
http://dx.doi.org/10.3389/fonc.2019.00379

Ejemplares similares